Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors-Reference-Cited by-同舟云学术

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

Published:2024-01 Issue:01 Volume:11 Page:086-099
ISSN:2699-9404
Container-title:Global Medical Genetics
language:en
Short-container-title:Glob Med Genet

Author:

Xu Chunwei¹²,Wang Qian³,Wang Dong²,Wang Wenxian⁴,Fang Wenfeng⁵,Li Ziming⁶,Liu Aijun⁷,Yu Jinpu⁸,Zhong Wenzhao⁹,Wang Zhijie¹⁰,Zhang Yongchang¹¹,Liu Jingjing¹²,Zhang Shirong¹³,Cai Xiuyu¹⁴,Liu Anwen¹⁵,Li Wen¹⁶,Zhan Ping²,Liu Hongbing²,Lv Tangfeng²,Miao Liyun¹⁷,Min Lingfeng¹⁸,Chen Yu¹⁹,Yuan Jingping²⁰,Wang Feng²¹,Jiang Zhansheng²²,Lin Gen¹⁹,Huang Long¹⁵,Pu Xingxiang²³,Lin Rongbo¹⁹,Liu Weifeng²⁴,Rao Chuangzhou²⁵,Lv Dongqing²⁶,Yu Zongyang²⁷,Li Xiaoyan²⁸,Tang Chuanhao²⁹,Zhou Chengzhi³⁰,Zhang Junping³¹,Xue Junli³²,Guo Hui³³,Chu Qian³⁴,Meng Rui³⁵,Wu Jingxun³⁶,Zhang Rui³⁷,Zhou Jin³⁸,Zhu Zhengfei³⁹,Li Yongheng⁴⁰,Qiu Hong³⁴,Xia Fan³⁹,Lu Yuanyuan⁴¹,Chen Xiaofeng⁴²,Ge Rui⁴³,Dai Enyong⁴⁴,Han Yu⁴⁵,Pan Weiwei⁴⁶,Pang Fei⁴⁷,He Qingqing⁴⁷,Huang Jintao⁴⁷,Wang Kai⁴⁷,Wu Fan⁴⁸,Xu Bingwei⁴⁹,Wang Liping⁵⁰,Zhu Youcai⁵¹,Lin Li²⁹,Xie Yanru⁵²,Lin Xinqing³⁰,Cai Jing¹⁵,Xu Ling⁵³,Li Jisheng⁵⁴,Jiao Xiaodong⁵⁵,Li Kainan⁵⁶,Wei Jia⁵⁷,Feng Huijing³¹,Wang Lin⁵⁸,Du Yingying⁵⁹,Yao Wang⁶⁰,Shi Xuefei⁶¹,Niu Xiaomin⁶,Yuan Dongmei²,Yao Yanwen²,Huang Jianhui⁵²,Feng Yue⁶²,Zhang Yinbin⁶³,Sun Pingli⁶⁴,Wang Hong⁶⁵,Ye Mingxiang²,Wang Zhaofeng²,Hao Yue⁴,Wang Zhen⁶⁶,Wan Bin⁶⁷,Lv Donglai⁶⁸,Yang Shengjie⁶⁹,Kang Jin⁹,Zhang Jiatao⁹,Zhang Chao⁹,Ou Juanjuan⁷⁰,Shi Lin⁷¹,Wang Yina⁷²,Li Bihui⁷³,Zhang Zhang⁷⁴,Li Zhongwu⁷⁵,Liu Zhefeng⁶⁵,Yang Nong¹¹,Wu Lin²³,Wang Huijuan⁷⁶,Jin Gu⁷⁷,Wang Guansong⁷⁸,Wang Jiandong⁷⁹,Fang Meiyu³,Fang Yong⁸⁰,Li Yuan⁸¹,Wang Xiaojia⁴,Zhang Yiping⁴,Zhu Xixu⁶⁶,Shen Yi⁸²,Ma Shenglin⁸³,Wang Biyun⁸⁴,Si Lu⁸⁵,Song Yong²,Lu Yuanzhi⁸⁶,Chen Jing³⁵,Song Zhengbo⁴

Affiliation:

1. Department of Scientific Research, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou Zhejiang, People's Republic of China

2. Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing Jiangsu, People's Republic of China

3. Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing Jiangsu, People's Republic of China

4. Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China

5. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou Guangdong, People's Republic of China

6. Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China

7. Senior Department of Pathology, the 7th Medical Center of PLA General Hospital, Beijing, People's Republic of China

8. Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China

9. Department of Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou Guangdong, People's Republic of China

10. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China

11. Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha Hunan, People's Republic of China

12. Department of Thoracic Cancer, Jilin Cancer Hospital, Jilin Changchun, People's Republic of China

13. Department of Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou Zhejiang, People's Republic of China

14. Department of VIP Inpatient, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People's Republic of China

15. Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang Jiangxi, People's Republic of China

16. Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou Zhejiang, People's Republic of China

17. Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing Jiangsu, People's Republic of China

18. Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou Jiangsu, People's Republic of China

19. Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou Fujian, People's Republic of China

20. Department of Pathology, Renmin Hospital of Wuhan University, Wuhan Hubei, People's Republic of China

21. Department of Internal Medicine, Cancer Center of PLA, Qinhuai Medical Area, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, People's Republic of China

22. Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China

23. Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha Hunan, People's Republic of China

24. Department of Orthopaedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing, People's Republic of China

25. Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo Zhejiang, People's Republic of China

26. Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou Zhejiang, People's Republic of China

27. Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou Fujian, People's Republic of China

28. Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

29. Department of Medical Oncology, Peking University International Hospital, Beijing, People's Republic of China

30. Department of State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou Guangdong, People's Republic of China

31. Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan Shanxi, People's Republic of China

32. Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China

33. Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi, People's Republic of China

34. Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei, People's Republic of China

35. Department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei, People's Republic of China

36. Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen Fujian, People's Republic of China

37. Department of Medical Oncology, Cancer Hospital of China Medical University, Shenyang Liaoning, People's Republic of China

38. Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology, Chengdu Sichuan, People's Republic of China

39. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China

40. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China

41. Department of State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an Shaanxi, People's Republic of China

42. Department of Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing Jiangsu, People's Republic of China

43. Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China

44. Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun Jilin, People's Republic of China

45. Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin Heilongjiang, People's Republic of China

46. Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing Zhejiang, People's Republic of China

47. Department of Medical, Shanghai OrigiMed Co., Ltd., Shanghai, People's Republic of China

48. Department of Medical, Stone Pharmaceuticals (Suzhou) Co., Ltd., Shanghai, People's Republic of China

49. Department of Biotherapy, Cancer Institute, First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China

50. Department of Oncology, Baotou Cancer Hospital, Baotou Inner Mongolia, People's Republic of China

51. Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang, People's Republic of China

52. Department of Oncology, Lishui Municipal Central Hospital, Lishui Zhejiang, People's Republic of China

53. Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei Anhui, People's Republic of China

54. Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinnan Shangdong, People's Republic of China

55. Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, People's Republic of China

56. Department of Oncology, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan Shandong, People's Republic of China

57. Department of the Comprehensive Cancer Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing Jiangsu, People's Republic of China

58. Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan Shanxi, People's Republic of China

59. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei Anhui, People's Republic of China

60. Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou Guangdong, People's Republic of China

61. Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou Zhejiang, People's Republic of China

62. Department of Gynecologic Radiation Oncology, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China

63. Department of Oncology, the Second Affiliated Hospital of Medical College, Xi′an Jiaotong University, Xi'an Shaanxi, People's Republic of China

64. Department of Pathology, The Second Hospital of Jilin University, Changchun Jilin, People's Republic of China

65. Senior Department of Oncology, The 5th Medical Center of PLA General Hospital, Beijing, People's Republic of China

66. Department of Radiation Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, People's Republic of China

67. Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing Jiangsu, People's Republic of China

68. Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei Anhui, People's Republic of China

69. Department of Thoracic Surgery, Chuxiong Yi Autonomous Prefecture People's Hospital, Chuxiong, People's Republic of China

70. Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People's Republic of China

71. Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China

72. Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou Zhejiang, People's Republic of China

73. Department of Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin Guangxi, People's Republic of China

74. Department of International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou, Guangdong, People's Republic of China

75. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China

76. Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou Henan, People's Republic of China

77. Department of Bone and Soft-tissue Surgery, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou Zhejiang, People's Republic of China

78. Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, People's Republic of China

79. Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, People's Republic of China

80. Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou Zhejiang, People's Republic of China

81. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China

82. Department of Thoracic Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing Jiangsu, People's Republic of China

83. Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou Zhejiang, People's Republic of China

84. Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China

85. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China

86. Department of Clinical Pathology, the First Affiliated Hospital of Jinan University, Guangzhou Guangdong, People's Republic of China

Abstract

AbstractThe fusion genes NRG1 and NRG2, members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, NRG1 retains its EGF-like active domain, binds to the ERBB ligand family, and triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. CD74 and SLC3A2 are the most frequently observed fusion partners. RNA-based next-generation sequencing is the primary method for detecting NRG1 and NRG2 gene fusions, whereas pERBB3 immunohistochemistry can serve as a rapid prescreening tool for identifying NRG1-positive patients. Currently, there are no approved targeted drugs for NRG1 and NRG2. Common treatment approaches involve pan-ERBB inhibitors, small molecule inhibitors targeting ERBB2 or ERBB3, and monoclonal antibodies. Given the current landscape of NRG1 and NRG2 in solid tumors, a consensus among diagnostic and treatment experts is proposed, and clinical trials hold promise for benefiting more patients with NRG1 and NRG2 gene fusion solid tumors.

Publisher

Georg Thieme Verlag KG

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0044-1781457.pdf

Reference58 articles.

1. Oncogenic kinase signalling;P Blume-Jensen;Nature,2001

2. Neuregulins: functions, forms, and signaling strategies;D L Falls;Exp Cell Res,2003

3. Detection of NRG1 gene fusions in solid tumors;S Jonna;Clin Cancer Res,2019

4. Identification of novel CD74-NRG2α fusion from comprehensive profiling of lung adenocarcinoma in Japanese never or light smokers;S Kohsaka;J Thorac Oncol,2020

5. Identification of novel CDH1-NRG2α and F11R-NRG2α fusions in NSCLC plus additional novel NRG2α fusions in other solid tumors by whole transcriptome sequencing;S I Ou;JTO Clin Res Rep,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse tumors: Molecular determinants shared by different cancer types;Computers in Biology and Medicine;2024-08